NOACs: Management of bleeding under NOAC therapy

Evaluation

NOAC dosage and last intake time.
Co-medications: antiplatelets, NSAIDs, alcohol, and OTC drugs.
Blood tests for creatinine, liver function, and CBC.
Rapid coagulation assessment and plasma drug level (if available).

Laboratory assessment in anticoagulated patients with clinically relevant bleeding or requiring urgent procedures

Vitamin K antagonists

First-Line Test:

PT/INR

Interpretation:

INR reflects anticoagulant intensity and guides reversal decisions

Specialized assays (if available):

N/A

Considerations:

In DIC or liver dysfunction, INR may be unreliable

Unfractionated heparin (UFH)

First-Line Test:

aPTT

Interpretation:

aPTT ↑ = anticoagulant effect present

Specialized assays (if available):

Anti-FXa (UFH-calibrated) if aPTT unreliable (e.g. lupus anticoagulant, low fibrinogen)

Considerations:

Protamine fully reverses UFH; results affected by hypofibrinogenemia and liver failure

Low-molecular-weight heparin (LMWH)

First-Line Test: -

Interpretation:

PT/aPTT not reliable for LMWH

Specialized assays (if available):

Anti-FXa (LMWH-calibrated) for quantification in renal impairment, pregnancy, obesity, or major bleeding

Considerations:

Protamine provides partial reversal; peak levels ∼4 h after last dose

Fondaparinux

First-Line Test: -

Interpretation:

PT/aPTT not informative

Specialized assays (if available):

Anti-FXa (fondaparinux-calibrated) if available

Considerations:

No specific antidote; rFVIIa/aPCC may be considered in refractory cases

Dabigatran

First-Line Test:

TT ± aPTT

Interpretation:

Normal TT → excludes relevant levels;

prolonged aPTT → suggests on- or above-therapy exposure;

normal aPTT does not exclude

Specialized assays (if available):

Dilute TT, Ecarin Clotting Time (ECT), or Ecarin Chromogenic Assay (ECA) for quantification; LC–MS/MS as gold standard

Considerations:

For life-threatening bleeding, SSC-ISTH suggests reversal if > 50 ng/mL; for high-risk procedures > 30 ng/mL

Rivaroxaban/Edoxaban/Betrixaban

First-Line Test: PT

Interpretation:

Prolonged PT → consistent with on/above-therapy levels; normal PT → does not exclude (reagent-dependent)

Specialized assays (if available):

Chromogenic anti-FXa assay calibrated with the specific drug;

LMWH/UFH-calibrated assays may exclude, not quantify

Considerations:

PT/aPTT are insensitive; normal values do not exclude clinically relevant concentrations

Bivalirudin/Argatrobana

First-Line Test:

aPTT (or ACT in procedure)

Interpretation:

aPTT ↑ expected; ACT used intra-procedurally

Specialized assays (if available):

dTT or ECT if available

Considerations:

Short half-life; rapid decline after discontinuation if organ function preserved

Bleeding definition

Mild bleeding (clinically relevant nonmajor bleeding)

Non-life-threatening major bleeding

Life-threatening- or bleeding into a critical site

Requiring medical intervention by a health care professional
Leading to hospitalization or increased level of care
Prompting a face-to-face evaluation

Clinically overt bleeding in excess of expected and
associated with a fall of 2 g of hemoglobin per dl and/or
leading to transfusion of > 2 U PRC or whole blood

Fetal bleeding
Symptomatic retroperitoneal, intracranial, intraocular or intraspinal bleeding

Any clinically overt sign of hemorrhage associated with a fall in hemoglobin of 3 to ≤5 g/dl or hematocrit of 9 to ≤15%
Requiring medical attention:(and does not meet criteria for major or minor bleeding)

-Bleeding requiring intervention
-Bleeding leading to prolonged hospitalisation
-Bleeding prompting evaluation

Clinically overt hemorrhage with > 5 g/dL decrease in Hb (hematocrit of >15%)

Intracranial bleeding
Fetal bleeding (death within 7 days)

Bleed without blood transfusion or hemodynamic compromise

Bleeding requiring transfusion of whole blood or PRBC without hemodynamic compromise.

Any of the following
- Fatal
- Intracranial
- Bleeding that caused
- hemodynamic compromise requiring intervention (eg, SBP<90 mmHg that required blood or fluid replacement, vasopressor/inotropic support, or surgical intervention)

Management

Delay or discontinue the next dose
Reconsider concomitant medication
Reconsider the choice of NOAC & dosing

Supportive
- Mechanical compression
- GI bleeding: Endoscopic hemostasis
- Surgical hemostasis
- Fluid replacement; RBC/ platelet substitution
- Consider adjuvant tranexamic acid
- Treatment of factors/ comorbidities contributing to bleeding
For dabigatran:
- Consider idarucizumab

or hemodialysis (if idarucizumab is not available)

Dabigatran: idarucizumab 5 g i.v.
- Idarucizumab 5 g i.v. in 2 consecutive infusions of 2.5g i.v. over 5-10 minutes each (or as a bolus)

Factor Xa inhibitor: Andexanet alpha (see below)

Otherwise, consider:
PCC 50 U/kg; + 25 U/kg if indicated
aPCC 50 U/kg: max 200 U/kg/day

Andexanet alpha

Dose of Factor Xa inhibitor

Apixaban ≤ 5 mg or Rivaroxaban ≤ 10 mg or Edoxaban ≤ 30 mg

Apixaban > 5 mg or Rivaroxaban > 10 mg or Edoxaban > 30 mg

Timing of last dose

< 8 hours

≥ 8 hours

Low dose: Bolus 400 mg (at 30 mg/min) then infusion 4 mg/min over two hours (480 mg).

Post-bleeding management

- Discuss how bleeding affects the patient's evaluation of the risks and benefits of anticoagulation.
- Assess the risk of recurrent bleeding.
- Re-evaluate modifiable factors that contribute to bleeding risk.
- Review the correct selection and dosing of NOACs (Novel Oral Anticoagulants).
- Re-initiate anticoagulation in the absence of absolute contraindications, using a shared decision-making approach.

References

Jan Steffel, Ronan Collins, Matthias Antz, Pieter Cornu, Lien Desteghe, Karl Georg Haeusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Thomas Vanassche, Tatjana Potpara, A John Camm, Hein Heidbüchel, External reviewers , 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation, EP Europace, Volume 23, Issue 10, October 2021, Pages 1612–1676, https://doi.org/10.1093/europace/euab065

Galli M, Simeone B, Ten Berg J, Capodanno D, Valgimigli M, Sciarretta S, Greco E, Kastrati A, Montalescot G, Gibson CM, Gorog DA, Mehran R, Angiolillo DJ. Managing bleeds on anticoagulant therapy: a practical guide for clinicians. Eur Heart J Acute Cardiovasc Care. 2026 Jul 8;15(7):557-572. doi: 10.1093/ehjacc/zuag035. PMID: 41818678; PMCID: PMC13344178.